Literature DB >> 6930611

Salivary lithium concentration--a tool for monitoring psychiatric patients.

H Ben-Aryeh, H Naon, R Szargel, D Gutman, A Hefetz.   

Abstract

Salivary and serum lithium concentrations were measured simultaneously in 118 manic-depressive patients. Lithium concentration in saliva was 2.24 +/- 0.35 times higher than in serum. An equation to calculate serum lithium concentration from salivary measurements was derived: Li serum = 0.36 Li saliva + 0.13. Psychotropic drugs had no effect on the salivary:serum ratio. Eighteen patients were followed for several weeks. A significant correlation coefficient between salivary and serum lithium concentrations was found in thirteen of the eighteen patients studied.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6930611     DOI： 10.1016/0030-4220(80)90198-x

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol        ISSN： 0030-4220


  4 in total

1.  Saliva testing as a means to monitor therapeutic lithium levels in patients with psychiatric disorders: Identification of clinical and environmental covariates, and their incorporation into a prediction model.

Authors:  Georgia M Parkin; Michael J McCarthy; Soe H Thein; Hillary L Piccerillo; Nisha Warikoo; Douglas A Granger; Elizabeth A Thomas
Journal:  Bipolar Disord       Date:  2021-09-24       Impact factor: 5.345

2.  A high performance liquid chromatographic assay of mefloquine in saliva after a single oral dose in healthy adult Africans.

Authors:  Grace O Gbotosho; Christian T Happi; Omowunmi Lawal; Abayomi Sijuade; Akin Sowunmi; Ayoade Oduola
Journal:  Malar J       Date:  2012-02-27       Impact factor: 2.979

Review 3.  Advances in Therapeutic Monitoring of Lithium in the Management of Bipolar Disorder.

Authors:  Mahsa Sheikh; Meha Qassem; Iasonas F Triantis; Panicos A Kyriacou
Journal:  Sensors (Basel)       Date:  2022-01-19       Impact factor: 3.576

4.  Provider Perspectives on the Current Use of Lithium Medications and Lithium Monitoring Practices for Psychiatric Conditions.

Authors:  Georgia M Parkin; Elizabeth A Thomas
Journal:  Neuropsychiatr Dis Treat       Date:  2022-09-15       Impact factor: 2.989
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.